Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors.
Yan LiPu KuangHuanling ZhuLing PanTian DongTing LinYu ChenYunfan YangPublished in: Therapeutic advances in hematology (2024)
Lowering the TKI dose can effectively preserve a deep molecular response over time while relieving adverse events caused by TKIs.